Marc Sim1, Richard L Prince2, David Scott3, Robin M Daly4, Gustavo Duque5, Charles A Inderjeeth6, Kun Zhu2, Richard J Woodman7, Jonathan M Hodgson8, Joshua R Lewis9. 1. School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia; Medical School, Royal Perth Hospital Unit, The University Western Australia, Perth, WA, Australia. Electronic address: marc.sim@ecu.edu.au. 2. Medical School, The University Western Australia, Perth, WA, Australia; Department of Endocrinology and Diabetes, Sir Charles Gairdner Hospital, Nedlands, WA, Australia. 3. Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia; Department of Medicine and Australian Institute of Musculoskeletal Science, Melbourne Medical School-Western Campus, The University of Melbourne, St Albans, VIC, Australia. 4. Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, VIC, Australia. 5. Department of Medicine and Australian Institute of Musculoskeletal Science, Melbourne Medical School-Western Campus, The University of Melbourne, St Albans, VIC, Australia; Department of Medicine-Western Health, Melbourne Medical School, The University of Melbourne, Melbourne, VIC, Australia. 6. Medical School, The University Western Australia, Perth, WA, Australia. 7. Flinders Centre for Epidemiology and Biostatistics, Flinders University, Adelaide, SA, Australia. 8. School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia; Medical School, Royal Perth Hospital Unit, The University Western Australia, Perth, WA, Australia. 9. School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia; Medical School, Royal Perth Hospital Unit, The University Western Australia, Perth, WA, Australia; Center for Kidney Research, Children's Hospital at Westmead, School of Public Health, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
Abstract
OBJECTIVES: To investigate the relationship of 4 sarcopenia definitions with long-term all-cause mortality risk in older Australian women. DESIGN: Data from the Perth Longitudinal Study in Aging Women from 2003 to 2013 was examined in this prospective cohort study. The 4 sarcopenia definitions were the United States Foundation for the National Institutes of Health (FNIH), the European Working Group on Sarcopenia in Older People (EWGSOP), and adapted FNIH (AUS-POPF) and EWGSOP (AUS-POPE) definitions using Australian population-specific cut-points [<2 standard deviation (SD)] below the mean of young healthy Australian women. All-cause mortality was captured via linked data systems. SETTING AND PARTICIPANTS: In total, 903 community-dwelling older Australian women (baseline mean age 79.9 ± 2.6 years) with concurrent measures of muscle strength (grip strength), physical function (timed-up-and-go; TUG) and appendicular lean mass (ALM) were included. MEASURES: Cox-proportional hazards modeling was used to examine the relationship between sarcopenia definitions and mortality over 5 and 9.5 years. RESULTS: Baseline prevalence of sarcopenia by the 4 definitions differed substantially [FNIH (9.4%), EWGSOP (24.1%), AUS-POPF (12.0%), AUS-POPE (10.7%)]. EWGSOP and AUS-POPE had increased age-adjusted hazard ratios (aHRs) for mortality over 5 years [aHR 1.88 95% confidence interval (CI) (1.24‒2.85), P < .01; aHR 2.52 95% CI (1.55‒4.09), P < .01, respectively] and 9.5 years (aHR 1.39 95% CI (1.06‒1.81), P = .02; aHR 1.94 95% CI (1.40‒2.69), P < .01, respectively). No such associations were observed for FNIH or AUS-POPF. Sarcopenia components including weaker grip strength (per SD, 4.9 kg; 17%) and slower TUG (per SD, 3.1 seconds; 40%) but not ALM adjusted-variants (ALM/body mass index or ALM/height2) were associated with greater relative hazards for mortality over 9.5 years. CONCLUSIONS/RELEVANCE: Unlike FNIH, the EWGSOP sarcopenia definition incorporating weak muscle strength and/or poor physical function was related to prognosis, as was the regionally adapted version of EWGSOP. Although sarcopenia definitions were not developed based on prognosis, this is an important consideration for globally standardizing the sarcopenia framework.
OBJECTIVES: To investigate the relationship of 4 sarcopenia definitions with long-term all-cause mortality risk in older Australian women. DESIGN: Data from the Perth Longitudinal Study in Aging Women from 2003 to 2013 was examined in this prospective cohort study. The 4 sarcopenia definitions were the United States Foundation for the National Institutes of Health (FNIH), the European Working Group on Sarcopenia in Older People (EWGSOP), and adapted FNIH (AUS-POPF) and EWGSOP (AUS-POPE) definitions using Australian population-specific cut-points [<2 standard deviation (SD)] below the mean of young healthy Australian women. All-cause mortality was captured via linked data systems. SETTING AND PARTICIPANTS: In total, 903 community-dwelling older Australian women (baseline mean age 79.9 ± 2.6 years) with concurrent measures of muscle strength (grip strength), physical function (timed-up-and-go; TUG) and appendicular lean mass (ALM) were included. MEASURES: Cox-proportional hazards modeling was used to examine the relationship between sarcopenia definitions and mortality over 5 and 9.5 years. RESULTS: Baseline prevalence of sarcopenia by the 4 definitions differed substantially [FNIH (9.4%), EWGSOP (24.1%), AUS-POPF (12.0%), AUS-POPE (10.7%)]. EWGSOP and AUS-POPE had increased age-adjusted hazard ratios (aHRs) for mortality over 5 years [aHR 1.88 95% confidence interval (CI) (1.24‒2.85), P < .01; aHR 2.52 95% CI (1.55‒4.09), P < .01, respectively] and 9.5 years (aHR 1.39 95% CI (1.06‒1.81), P = .02; aHR 1.94 95% CI (1.40‒2.69), P < .01, respectively). No such associations were observed for FNIH or AUS-POPF. Sarcopenia components including weaker grip strength (per SD, 4.9 kg; 17%) and slower TUG (per SD, 3.1 seconds; 40%) but not ALM adjusted-variants (ALM/body mass index or ALM/height2) were associated with greater relative hazards for mortality over 9.5 years. CONCLUSIONS/RELEVANCE: Unlike FNIH, the EWGSOP sarcopenia definition incorporating weak muscle strength and/or poor physical function was related to prognosis, as was the regionally adapted version of EWGSOP. Although sarcopenia definitions were not developed based on prognosis, this is an important consideration for globally standardizing the sarcopenia framework.
Authors: Nada Almohaisen; Matthew Gittins; Chris Todd; Jana Sremanakova; Anne Marie Sowerbutts; Amal Aldossari; Asrar Almutairi; Debra Jones; Sorrel Burden Journal: Nutrients Date: 2022-04-07 Impact factor: 6.706
Authors: X Yu; L Hou; J Guo; Y Wang; P Han; L Fu; P Song; X Chen; H Yu; Y Zhang; L Wang; W Zhang; X Zhu; F Yang; Q Guo Journal: J Nutr Health Aging Date: 2020 Impact factor: 4.075
Authors: Geraldo José de Amorim; Cinthia Katiane Martins Calado; Bruno Carlos Souza de Oliveira; Renata Patricia Oliveira Araujo; Tayrine Ordonio Filgueira; Matheus Santos de Sousa Fernandes; Angela Castoldi; Gisele Vajgel; Lucila Maria Valente; José Luiz de Lima-Filho; Paulo Roberto Cavalcanti Carvalho; Fabricio Oliveira Souto Journal: Front Med (Lausanne) Date: 2022-04-07
Authors: Sophia X Sui; Kara L Holloway-Kew; Natalie K Hyde; Lana J Williams; Monica C Tembo; Sarah Leach; Julie A Pasco Journal: J Clin Med Date: 2021-01-18 Impact factor: 4.241
Authors: Rebecca Knowles; Jennifer Carter; Susan A Jebb; Derrick Bennett; Sarah Lewington; Carmen Piernas Journal: J Am Heart Assoc Date: 2021-04-19 Impact factor: 5.501
Authors: Sara Peixoto da Silva; Joana M O Santos; Maria Paula Costa E Silva; Rui M Gil da Costa; Rui Medeiros Journal: J Cachexia Sarcopenia Muscle Date: 2020-03-06 Impact factor: 12.910